Bispecific Antibody Armed Metabolically Enhanced Headless CAR T Cells.
Antibodies, Bispecific
/ genetics
Breast Neoplasms
/ genetics
Coculture Techniques
Cytokines
/ metabolism
Cytotoxicity, Immunologic
ErbB Receptors
/ antagonists & inhibitors
Female
Humans
Immunotherapy, Adoptive
MCF-7 Cells
Phenotype
Receptor, ErbB-2
/ antagonists & inhibitors
Receptors, Chimeric Antigen
/ genetics
T-Lymphocytes
/ immunology
Tumor Hypoxia
Tumor Microenvironment
Th1 cytokines
activated T cells
bispecific antibody
breast cancer
co-activated T cells
headless CAR T cells
pancreatic cancer
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
02
04
2021
accepted:
17
06
2021
entrez:
22
7
2021
pubmed:
23
7
2021
medline:
28
10
2021
Statut:
epublish
Résumé
Adoptive T cell therapies for solid tumors is challenging. We generated metabolically enhanced co-activated-T cells by transducing intracellular co-stimulatory (41BB, ICOS or ICOS-27) and CD3ζ T cell receptor signaling domains followed by arming with bispecific antibodies (BiAbs) to produce armed "Headless CAR T cells" (hCART). Various hCART armed with BiAb directed at CD3ϵ and various tumor associated antigens were tested for: 1) specific cytotoxicity against solid tumors targets; 2) repeated and dual sequential cytotoxicity; 3) survival and cytotoxicity under
Identifiants
pubmed: 34290709
doi: 10.3389/fimmu.2021.690437
pmc: PMC8288104
doi:
Substances chimiques
Antibodies, Bispecific
0
Cytokines
0
Receptors, Chimeric Antigen
0
EGFR protein, human
EC 2.7.10.1
ERBB2 protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
690437Subventions
Organisme : NCI NIH HHS
ID : R01 CA140314
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA022453
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA226983
Pays : United States
Informations de copyright
Copyright © 2021 Thakur, Scholler, Kubicka, Bliemeister, Schalk, June and Lum.
Déclaration de conflit d'intérêts
LL is co-founder of Transtarget Inc. and serves on the SAB for Rapa Therapeutics, CJ is a co-founder of Tmunity Therapeutics, Inc. and AT is co-founder of AlphaImmunePlatform LLC. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cancer Immunol Immunother. 2012 Apr;61(4):497-509
pubmed: 21971587
Curr Med Chem. 2008;15(4):322-38
pubmed: 18288988
Annu Rev Immunol. 2019 Apr 26;37:145-171
pubmed: 30526160
J Transl Med. 2013 Feb 09;11:35
pubmed: 23394575
J Clin Oncol. 1998 Aug;16(8):2752-60
pubmed: 9704728
Nat Rev Cancer. 2004 Jun;4(6):437-47
pubmed: 15170446
Front Oncol. 2020 May 05;10:544
pubmed: 32432032
Cancer Cell. 2015 Oct 12;28(4):415-428
pubmed: 26461090
J Cancer Res Clin Oncol. 2020 Aug;146(8):2007-2016
pubmed: 32449004
BMC Cancer. 2013 Feb 22;13:83
pubmed: 23433400
Science. 2015 Apr 3;348(6230):62-8
pubmed: 25838374
Front Immunol. 2019 Feb 05;10:128
pubmed: 30804938
Cell. 2015 Sep 10;162(6):1229-41
pubmed: 26321679
Oncoimmunology. 2018 Aug 27;7(12):e1500672
pubmed: 30524893
JAMA Oncol. 2017 Aug 1;3(8):1094-1101
pubmed: 28426845
Immunity. 2016 Sep 20;45(3):701-703
pubmed: 27653602
Front Immunol. 2018 May 22;9:1104
pubmed: 29872437
Cell. 2016 Oct 20;167(3):829-842.e13
pubmed: 27745970
Clin Cancer Res. 2006 Jan 15;12(2):569-76
pubmed: 16428502
N Engl J Med. 2011 Aug 25;365(8):725-33
pubmed: 21830940
N Engl J Med. 2016 Dec 29;375(26):2561-9
pubmed: 28029927
Immunity. 2016 Mar 15;44(3):712
pubmed: 28843072
Nat Commun. 2015 Mar 26;6:6692
pubmed: 25809635
Science. 1988 Dec 9;242(4884):1412-5
pubmed: 2849206
Transplantation. 1993 Aug;56(2):351-6
pubmed: 8356589
Prostate Cancer. 2015;2015:285193
pubmed: 25802762
Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4547-52
pubmed: 17360561
Blood. 2011 Nov 3;118(18):4817-28
pubmed: 21849486
Nat Rev Immunol. 2015 Jan;15(1):45-56
pubmed: 25534622
J Exp Med. 2014 May 5;211(5):781-90
pubmed: 24778419
Clin Immunol Immunopathol. 1994 Mar;70(3):234-40
pubmed: 8313660
Oncoimmunology. 2017 Oct 16;7(2):e1380764
pubmed: 29308300
Oncoimmunology. 2015 Jul 15;5(3):e1055061
pubmed: 27141330
Mol Ther. 2013 Apr;21(4):904-12
pubmed: 23423337
Oncoimmunology. 2020 Jun 10;9(1):1773201
pubmed: 32939319
Cell. 2013 Jun 6;153(6):1239-51
pubmed: 23746840
J Hematother Stem Cell Res. 2001 Apr;10(2):247-60
pubmed: 11359672
Mol Immunol. 2015 Dec;68(2 Pt C):492-6
pubmed: 26256793
Clin Cancer Res. 2015 May 15;21(10):2305-14
pubmed: 25688159
N Engl J Med. 2011 Nov 3;365(18):1673-83
pubmed: 22047558
Cancer Discov. 2017 Nov;7(11):1306-1319
pubmed: 28801306
Immunol Lett. 2017 Dec;192:1-6
pubmed: 28987474
Eur J Immunol. 2008 Sep;38(9):2412-8
pubmed: 18792019
JCI Insight. 2018 Jan 11;3(1):
pubmed: 29321369